A Comparison of Seroquel vs. Risperidone in Schizophrenia | NCT00034905 | Trialant

Home
Search
Collections
Views
Audits

Terms of Service
Privacy Policy

A Comparison of Seroquel vs. Risperidone in Schizophrenia | NCT00034905 | Trialant

Studies
A Comparison of Seroquel vs. Risperidone in Schizophrenia

NCT00034905

Sponsor

AstraZeneca

Status

Completed

Last Update Posted

Jan 4, 2013Estimated

Enrollment

Not provided

Phase

Phase 4

Conditions

Schizophrenia

Interventions

quetiapine fumarate vs risperidone

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

NCT00034905

Obsolete or Duplicate NCT IDs

Not provided

Organization Study

5077US/0043

Secondary IDs

Not provided

Brief Title

A Comparison of Seroquel vs. Risperidone in Schizophrenia

Official Title

Not provided

Acronym

Not provided

Organization

AstraZenecaINDUSTRY

Status Module

Record Verification Date

Jan 2013

Overall Recruitment Status or Expanded Access Status

Completed

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Not provided

Start Date

Jul 2001

Primary Completion Date

Sep 2002Actual

Completion Date

Sep 2002Actual

First Submitted Date

May 2, 2002

First Submission Date that Met QC Criteria

May 2, 2002

First Posted Date

May 3, 2002Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jan 3, 2013

Last Update Posted Date

Jan 4, 2013Estimated

Sponsor/Collaborators Module

Responsible Party, by Official Title

Not provided

Lead Sponsor

AstraZenecaINDUSTRY

Collaborators

Not provided

Oversight Module

No data available

No data is available for this block.

Description Module

Brief Summary

The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.

Detailed Description

Not provided

Conditions Module

Conditions

Schizophrenia

Keywords

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Phase 4

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

Not provided

Arms/Interventions Module

Arm Groups

Not provided

Interventions

Name	Type	Description	Arm Group Labels	Other Names
quetiapine fumarate vs risperidone	Drug

Outcomes Module

No data available

No data is available for this block.

Eligibility Module

Eligibility Criteria

Inclusion Criteria

Male / Female, 18-65 years old
Schizophrenia (as per DSM IV)

Exclusion Criteria

Concurrent use of psychotropic medication
Does not fulfill moderately ill on CGI

Accepts Healthy Volunteers

No

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

65 Years

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Not provided

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
		Birmingham	Alabama		United States

References Module

No data available

No data is available for this block.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Jul 10, 2026

Removed Countries

Not provided

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

MeSH Terms

Intervention Browse Module

No data available

No data is available for this block.

Not provided

Intervention Model Description

Not provided

Primary Purpose

Treatment

Observational Model

Not provided

Time Perspective

Not provided

Masking Info

No data available

No data is available for this block.

Phoenix

Arizona

United States

Anaheim

California

United States

Cerritos

California

United States

Chula Vista

California

United States

Glendale

California

United States

Hawthorne

California

United States

Long Beach

California

United States

San Diego

California

United States

Santa Ana

California

United States

Torrance

California

United States

Farmington

Connecticut

United States

New Haven

Connecticut

United States

Washington D.C.

District of Columbia

United States

Miami

Florida

United States

Miami Beach

Florida

United States

North Miami

Florida

United States

Winter Park

Florida

United States

Atlanta

Georgia

United States

Hoffman Estates

Illinois

United States

Prairie Village

Kansas

United States

Wichita

Kansas

United States

New Orleans

Louisiana

United States

Shreveport

Louisiana

United States

Baltimore

Maryland

United States

Boston

Massachusetts

United States

Worcester

Massachusetts

United States

Ann Arbor

Michigan

United States

New Baltimore

Michigan

United States

Kansas City

Missouri

United States

St Louis

Missouri

United States

Reno

Nevada

United States

Clementon

New Jersey

United States

Lyons

New Jersey

United States

Summit

New Jersey

United States

Albuquerque

New Mexico

United States

Holliswood

New York

United States

Montrose

New York

United States

New York

New York

United States

Oceanside

New York

United States

The Bronx

New York

United States

White Plains

New York

United States

Butner

North Carolina

United States

Beachwood

Ohio

United States

Chagrin Falls

Ohio

United States

Cincinnati

Ohio

United States

Columbus

Ohio

United States

Oklahoma City

Oklahoma

United States

Media

Pennsylvania

United States

Pittsburgh

Pennsylvania

United States

Memphis

Tennessee

United States

Nashville

Tennessee

United States

Austin

Texas

United States

Houston

Texas

United States

Terrell

Texas

United States

Waco

Texas

United States

Salt Lake City

Utah

United States

Falls Church

Virginia

United States

Richmond

Virginia

United States

Virginia Beach

Virginia

United States

Kirkland

Washington

United States

Tacoma

Washington

United States

Vancouver

Washington

United States

West Allis

Wisconsin

United States

ID	Term
D012559	Schizophrenia

Ancestor Terms

ID	Term
D019967	Schizophrenia Spectrum and Other Psychotic Disorders
D001523	Mental Disorders

Browse Leaves

Not provided

Browse Branches

Not provided